Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands

Executive Summary

The biotech startups that will be supported by a new transatlantic public-private partnership could end up with innovative products enticing enough to get some large biopharmaceutical firms back into the antibiotic game.

Advertisement

Related Content

AMR Roundtable: Optimism About CARB-X's Success And Prospects For The Future (Part 2)
AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed
Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances
Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review
BIO 2015 Dispatches: Enough ideas, plans; time for action on antimicrobial resistance
Superbug summit: White House to hold antibiotics forum
US Capitol Capsule: Obama superbug attack plan hinges on funding, cooperation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel